Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that must be diagnosed early to increase drug therapy efficacy. No early definitive diagnostic tool, however, is currently available, thus prompting for the identification of biomarkers of the disease. Isoprostanes (iPs) are prostaglandin-related free radical oxidation products of polyunsaturated fatty acids (PUFA) that are produced under oxidative stress conditions that occur, for instance, in the brain of AD sufferers. iPs are stable lipids known to partition in bodily fluids and are thus interesting potential biomarkers of AD. However, resolution of iPs by reverse phase HPLC is complicated by the existence of multiple regioisomers and enantiomers. Consequently, we have developed two normal phase chiral approaches for the detailed analysis of the F2-iP class of isoprostanes. First, normal phase chiral LC-MS/MS permitted the identification and quantification of four types of F2- iPs in urine samples from control, mild cognitive impairment (MCI) patients and severe AD sufferers. Second, given its suitability for non-polar compounds analysis and chiral separations, supercritical fluid chromatography (SFC) was investigated as an alternative approach. SFC-MS/MS enabled the identification of regioisomers and enantiomers of F2-iPs. Identification of analytes was undertaken by MRM monitoring of diagnostic transitions while the chiral chromatography allowed for the resolution of enantiomers within types. F-iPs could be reproducibly identified and quantified.
Keywords: Supercritical fluid chromatography, SFC, mass spectrometry, chiral separation, isoprostanes, Alzheimer’s disease.
Current Analytical Chemistry
Title:Investigation of Isoprostanes as Potential Biomarkers for Alzheimer's Disease Using Chiral LC-MS/MS and SFC-MS/MS
Volume: 10 Issue: 1
Author(s): Victoria Goss, Amaury Cazenave-Gassiot, Ashley Pringle and Anthony Postle
Affiliation:
Keywords: Supercritical fluid chromatography, SFC, mass spectrometry, chiral separation, isoprostanes, Alzheimer’s disease.
Abstract: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that must be diagnosed early to increase drug therapy efficacy. No early definitive diagnostic tool, however, is currently available, thus prompting for the identification of biomarkers of the disease. Isoprostanes (iPs) are prostaglandin-related free radical oxidation products of polyunsaturated fatty acids (PUFA) that are produced under oxidative stress conditions that occur, for instance, in the brain of AD sufferers. iPs are stable lipids known to partition in bodily fluids and are thus interesting potential biomarkers of AD. However, resolution of iPs by reverse phase HPLC is complicated by the existence of multiple regioisomers and enantiomers. Consequently, we have developed two normal phase chiral approaches for the detailed analysis of the F2-iP class of isoprostanes. First, normal phase chiral LC-MS/MS permitted the identification and quantification of four types of F2- iPs in urine samples from control, mild cognitive impairment (MCI) patients and severe AD sufferers. Second, given its suitability for non-polar compounds analysis and chiral separations, supercritical fluid chromatography (SFC) was investigated as an alternative approach. SFC-MS/MS enabled the identification of regioisomers and enantiomers of F2-iPs. Identification of analytes was undertaken by MRM monitoring of diagnostic transitions while the chiral chromatography allowed for the resolution of enantiomers within types. F-iPs could be reproducibly identified and quantified.
Export Options
About this article
Cite this article as:
Goss Victoria, Cazenave-Gassiot Amaury, Pringle Ashley and Postle Anthony, Investigation of Isoprostanes as Potential Biomarkers for Alzheimer's Disease Using Chiral LC-MS/MS and SFC-MS/MS, Current Analytical Chemistry 2014; 10 (1) . https://dx.doi.org/10.2174/1573411011410010010
DOI https://dx.doi.org/10.2174/1573411011410010010 |
Print ISSN 1573-4110 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6727 |
Call for Papers in Thematic Issues
Advancements in biomedicine, corrosion inhibition/monitoring, and lubrication of carbon dots
Carbon dots, a class of carbon-based nanomaterials, have garnered substantial interest in various scientific and engineering fields due to their unique properties, including excellent optical properties, outstanding biocompatibility, easy preparation, good dispersity, ultrasmall size, low toxicity and environmental friendliness. This special issue of Current Analytical Chemistry aims to showcase cutting-edge ...read more
Analytical methods for environmental and food analysis
In recent years, the study of the chemical composition of food and the environment depends on analytical methods in order to acquire information about the chemical composition, processing, quality control and contamination of soil, water, air, plants and foods, aspects very important for food safety and environmental quality control. There ...read more
Applications of artificial intelligence in chemical analysis
Artificial intelligence (AI) has demonstrated its versatility in almost all scientific fields, especially analytical chemistry, which is leading the way in the integration of AI. According to Chemical Abstract Services, one of the major disciplines contributing to AI-related publications and patents is analytical chemistry. That?s because techniques such as deep ...read more
Bioanalytical and Biosensor Technologies for Target Molecules
Bioanalytical and biosensor technologies constitute the core of detecting and sensing diverse molecules within living organisms, encompassing proteins, DNA, small molecular metabolites, and beyond. These molecules assume pivotal roles in biological processes, rendering their analysis and sensing indispensable for comprehending biological phenomena and unraveling disease mechanisms. In the current landscape ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Other Proteins Involved in Parkinson's Disease and Related Disorders
Current Protein & Peptide Science 3-Bromopyruvate: A New Targeted Antiglycolytic Agent and a Promise for Cancer Therapy
Current Pharmaceutical Biotechnology Efficacy and Toxicity of Clioquinol Treatment and A-beta42 Inoculation in the APP/PSI Mouse Model of Alzheimer's Disease
Current Alzheimer Research Metabotropic Glutamate Receptors (mGluRs) and Diabetic Neuropathy
Current Drug Targets Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Peripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases
Mini-Reviews in Medicinal Chemistry Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Preface: Highlights of Recent Progress in Alzheimers Disease Research [ Hot Topics in Alzheimers Disease Research (Guest Editor: Debomoy K. Lahiri)]
Current Drug Targets Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism Elevated Homocysteine Levels in Parkinsons Disease: Is there Anything Besides L-Dopa Treatment?
Current Medicinal Chemistry Non-Viral Methods For Generating Integration-Free, Induced Pluripotent Stem Cells
Current Stem Cell Research & Therapy Metformin - The Drug for the Treatment of Autoimmune Diseases; A New Use of a Known Anti-Diabetic Drug
Current Topics in Medicinal Chemistry Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology Expression Analysis of 4-Hydroxynonenal Modified Proteins in Schizophrenia Brain; Relevance to Involvement in Redox Dysregulation
Current Proteomics Alterations in Glucose Metabolism in Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Experimental and Clinical Advances in Immunotherapy Strategies for Spinal Cord Injury Target on MAIs and Their Receptors
Current Pharmaceutical Design Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design Gels and Jellies as a Dosage Form for Dysphagia Patients: A Review
Current Drug Therapy Hybrid Molecules Incorporating Natural Products: Applications in Cancer Therapy, Neurodegenerative Disorders and Beyond
Current Medicinal Chemistry Establishment of Method for the Determination of Aggregated α-Synuclein in DLB Patient Using RT-QuIC Assay
Protein & Peptide Letters